Form 4: CORT CFO Atabak Mokari Executes Stock Transactions

Corcept Therapeutics CFO Atabak Mokari exercised options and sold 40,000 shares of common stock under a 10b5-1 trading plan.

Summary

• CFO Atabak Mokari exercised options to acquire 40,000 shares of Corcept Therapeutics (CORT) at a price of $19.26 per share.
• Following the exercise, the CFO sold the 40,000 shares at a weighted average price of $70.0001 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025.
• The reporting person also acquired additional shares through a company purchase plan and had shares withheld for tax obligations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is standard for executive financial planning.

Positives

• The transaction demonstrates the exercise of long-term equity incentives by a key executive.
• The sale was conducted via a pre-arranged 10b5-1 plan, which is a standard mechanism for executives to manage personal liquidity without signaling negative sentiment.

Negatives

• The transaction results in a reduction of the CFO's direct beneficial ownership of common stock.

Risks

• Reliance on 10b5-1 plans does not eliminate the potential for market volatility following large insider sales.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine practice for executives in the biotechnology sector to diversify personal holdings and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of 10b5-1 plans is consistent with standard corporate governance practices for C-suite executives at publicly traded biotech firms.
• The scale of the transaction is typical for a CFO managing vested equity compensation.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and disclosed in accordance with SEC regulations.

Next Steps

• Future vesting of restricted stock awards as per the company's incentive plans.

Key Dates

Keywords

Corcept Therapeutics, CORT, Insider Trading, Form 4, CFO, Atabak Mokari, Equity Compensation